Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT02462759
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Connecticut Childrens Medical, Hartford, Connecticut, United States
🇺🇸The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT02460094
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, Medical Center at Parnassus, San Francisco, California, United States
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 66
- Registration Number
- NCT02459886
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT02443740
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 21
- Registration Number
- NCT02434718
- Locations
- 🇯🇵
Research Site, Kyoto, Japan
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 58
- Registration Number
- NCT02430532
- Locations
- 🇸🇰
Research Site, Banska Bystrica, Slovakia
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Biogen
- Registration Number
- NCT02428218
Tecfidera Slow-Titration Study
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 62
- Registration Number
- NCT02428231
- Locations
- 🇮🇹
Research Site, Montichiari, Italy
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT02422407
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
- Conditions
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 102
- Registration Number
- NCT02410278
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States